The Low Grade Glioma (LGG) is a type of brain tumor which is generally more common in younger age group patients. Most patients with LGG undergo surgery which is mostly incomplete due to concern about loss of function. This is incureable disease. More than half of these patients progress to higher grade with worse outcome within five years of their diagnosis and only one-third survive for up to ten years. Post-operative radiation treatment improves local control without survival advantage. Efforts being made without great success to select the patients with higher risk of progression based on physical characteristics and histological features.

Tumor vascularity is thought to be the key element in tumor progression. Tremendous progress has been made in functional imaging by using MRI 3T and in biotechnology which can be used to investigate angiogenic gene profiles in order to identify gene signature for these tumors. In this study we are proposing that patients of LGG with higher risk of tumor progression may be selected by functional imaging and angiogenic profiles. These higher risk patients may be candidate for post-operative radiation in future with potential survival benefit.

Condition	Intervention
-glioma	Device: imaging and angiogenic profiles

Further Study Details: 

Expected Total Enrollment:  10

Summary: Comprehensive analysis of the angiogenesis-related gene expression profiles and tumor perfusion of patients with LGG will provide a novel understanding of subgroup (low and high-risk) of LGG. Thus, this study will allow identifying clinically relevant factors predictive for tumor progression and to select patients in high-risk group for adjuvant radiation therapy.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• greater than 18 years of age
• brain tumor with no contrast enhancement on conventional MRI and confirmed histological of LGG
• no adjustment treatment
• consent to participate in study
• no contra-indication for DCE and MRI

Exclusion Criteria:

-

Please refer to this study by ClinicalTrials.gov identifier  NCT00137488

Bassam Abdulkarim, MD      780-432-8516    bassamab@cancerboard.ab.ca

Canada, Alberta
      Cross Cancer Institute, Edmonton,  Alberta,  T6G 1Z2,  Canada; Recruiting

Study chairs or principal investigators

Bassam Abdulkarim, MD,  Principal Investigator,  Alberta Cancer Board   

Study ID Numbers:  CNS-09-0024
Last Updated:  August 29, 2005
Record first received:  August 26, 2005
ClinicalTrials.gov Identifier:  NCT00137488
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-30